Abstract
We determined the in vitro activity of the novel orotomide antifungal, F901318, against 30 Lomentospora prolificans, 20 Scedosporium apiospermum, 7 S. aurantiacum, and 3 S. boydii, isolates in comparison with standard antifungals. Against L. prolificans, F901318 was the most potent compound (MIC90 0.25 μg/ml); the geometric mean MIC (0.26 μg/ml) was significantly lower (23-80-fold) than those of itraconazole, voriconazole, posaconazole, and isavuconazole (all P < .001), and amphotericin B (P < .05). F901318 also had good activity against S. apiospermum, S. aurantiacum, and S. boydii, comparable to that of voriconazole and posaconazole but was more active than isavuconazole for all three species.
Cite
CITATION STYLE
Biswas, C., Law, D., Birch, M., Halliday, C., Sorrell, T. C., Rex, J., … Chen, S. C. A. (2018). In vitro activity of the novel antifungal compound F901318 against Australian Scedosporium and Lomentospora fungi. Medical Mycology, 56(8), 1050–1054. https://doi.org/10.1093/mmy/myx161
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.